Seeking Alpha

Brian Marckx

View as an RSS Feed
View Brian Marckx's Comments BY TICKER:
Latest  |  Highest rated
  • BioLife Solutions Posts Another Record Year With Revenue Up 58% [View article]
    More shares will be issued with the debt conversion. As far as the RS, it's not uncommon for the share price to languish afterwards. It's an easier exit for those that were waiting to. But, BLFS did it to uplist and I think very legitimately so. This wasn't a RS so insiders could get out quick and then watch the stock tank.
    Feb 20 11:44 AM | 2 Likes Like |Link to Comment
  • Scrutiny Over Medical Device Safety Offers Opportunity For VeriTeQ [View article]
    Thanks for the comment.
    I fully expect the company will be cash flow negative and need to raise a fairly substantial amount of add'l capital over the next few years. That doesn't necessarily mean it has to come from one investor or mean the company has to be bought for current shareholders to see a positive return. My model assumes they sell new equity on an ongoing basis. Lots of companies run in the red for years prior to becoming profitable and generating positive cash flow. Will VTEQ eventually turn cash flow positive? I don't know. There's a lot of risk that d/n happen - just as there's a lot of risks with almost any development stage or early revenue stage co.
    Feb 14 02:09 PM | 1 Like Like |Link to Comment
  • Several Catalysts To Reignite Growth At LED Medical [View article]
    Thanks John, I appreciate the comments!!!!
    Jan 27 10:03 AM | Likes Like |Link to Comment
  • Rockwell Steadies Itself For A Phase III Run-Up [View article]
    Slack,

    Yeah to answer that question involves a much bigger exercise and involves modeling RMTI. I don't formally cover the company anymore so I don't model it. An SFP-failure scenario doesn't require a model.

    Keep in mind though, even if the CRUISE studies hit the endpoints, there's still a lot of risk that SFP doesn't get FDA approved. I would expect the stock would react favorably though if the study results are positive - so if you're trading on the hope of positive results....
    Jun 28 02:33 PM | Likes Like |Link to Comment
  • Rockwell Steadies Itself For A Phase III Run-Up [View article]
    Yes, link below to the Ph IIb results.

    http://1.usa.gov/16Eivw3
    Jun 28 08:43 AM | Likes Like |Link to Comment
  • Rockwell Steadies Itself For A Phase III Run-Up [View article]
    Bite you're right about the cc. According to clinicaltrials.gov the primary endpoint was never changed (still is mean change from baseline). There's a secondary endpoint that's decrease in Hgb of >/= 1.0.

    http://1.usa.gov/1cqxmvj

    http://1.usa.gov/1cqxmvn
    Jun 27 10:28 AM | Likes Like |Link to Comment
  • Rockwell Steadies Itself For A Phase III Run-Up [View article]
    Kory - CRUISE primary endpoint has always been mean change from baseline. I think some people may be confusing the various studies. Ph IIb used a primary endpoint of a drop in Hgb of 1.0 or more - which was a disaster. Ph IIb used a secondary endpoint of change from baseline - which, interestingly (or perhaps suspiciously), is being used as the primary endpoint in CRUISEs.
    Jun 26 12:11 PM | Likes Like |Link to Comment
  • Rockwell Steadies Itself For A Phase III Run-Up [View article]
    Bitesize,

    The Phase IIb was a 6-month trial, the CRUISE studies are 12-months. I think the longer length may benefit efficacy, particularly if mgmts. theories about protocol violations in Ph IIb are valid.

    The primary endpoint in CRUISE is not 0.5 g/dl decrease in Hgb. It's a statistically significant mean change from baseline between control and treatment - which is the same endpoint that was missed at every dose except one in Ph IIb.

    PRIME was a separate study focused on ESA reduction, not on maintaining Hgb.
    Jun 26 09:25 AM | Likes Like |Link to Comment
  • PST Launch, A New Inflection Point For Interleukin Genetics [View article]
    So you're saying BTIG is a bucket shop?
    The fact is that ILIU needed to raise money and they did - terms of the deal were not necessarily unfavorable to ILIU, particularly given their situation - they're a tiny company with low volume, were in a position where they needed $ immediately and were in a tight spot with their credit line.
    Clearly there's risk that ILIU may not eventually be profitable - it's a $14MM MC company trading at $0.40 - that risk already seems well baked in.
    Jun 24 03:20 PM | 1 Like Like |Link to Comment
  • PST Launch, A New Inflection Point For Interleukin Genetics [View article]
    The financing certainly had the effect of significantly increasing the share count. Importantly the company was able to raise a lot of $ when they needed to - whether they were going to be able to do so and avoid the impending liquidity crunch was a big question mark prior to the financing. They raised at $0.2745/share and the stock price has held up well since - which I think is indicative of the potential of PST. As you indicated, their prior commercialized products have not been successful enough to self-support the company - PST, with insurance reimbursement could be significantly more successful than their other tests, however.
    Jun 24 11:31 AM | 1 Like Like |Link to Comment
  • Rockwell Steadies Itself For A Phase III Run-Up [View article]
    slack,

    I think if SFP fails the stock is sub-$1.00. The only reason the stock trades as high as it does now and the reason RMTI was able to sell equity at $3.00 is the potential for SFP. In my opinion, there's almost no value in the company without SFP. Calictriol - I think best case scenario is that calcitriol might add $0.09 in annual EPS at peak sales - which isn't enough to get them to positive EPS even with totally eliminating R&D. Although RMTI may be able to eke out positive cash flow if they completely eliminate R&D (if, for instance SFP fails and they attempt to regroup), management has demonstrated a very unfriendly shareholder attitude that includes paying themselves hefty stock compensation - which leads me to believe the company will continue to generate net losses indefinitely if SFP fails.
    Jun 21 08:40 AM | Likes Like |Link to Comment
  • CryoPort's Game-Changer In Frozen Biological Shipping [View article]
    CYRX has survived on piecemeal raises over the years and they certainly need more $. The piecemeal raises have been drawn out longer than I think anyone expected which was a direct result of the slower than anticipated traction in onboarding customers. I think we'll see some more piecemeal over the very near term but with what looks like finally getting the business moving (kudos to current mgmt.), a bigger, more substantial financing which hopefully gets them to cash flow positive is hopefully in the cards in the not too distant future.
    Jun 19 12:02 PM | Likes Like |Link to Comment
  • Competitive Advantages, Huge Skin Cancer Market Bode Well For Aura [View article]
    Paul,

    This will be used as an adjunct or in place of "ABCD" but it's not competing with biopsy - biopsy will be the definitive diagnosis for the foreseeable future. So, yes, it's a matter of how comfortable doctors will be with using it at the initial diagnosis. If it's better than "ABCD", which it looks like it may be, then it makes sense that it has clinical utility.

    Re: capital raising, they had previously announced plans to raise up to $10 million via stock and warrants. They've only raised a small portion of that so far but I think it's safe to assume the company is looking for the best terms possible and expects to close on a stock sale in the near future.

    Re: MELA - I don't think the slow start has to do with a lack of a sizeable market. There's a few hurdles/questions though: derms being comfortable with using something novel, lack of reimbursement, whether the economics work for a particular derm practice, and does Melafind actually improve diagnosis. Time will likely provide some answers to these.

    Re: lung cancer application -timing is a big unknown right now. VRS is focused on skin right now but has had the benefit of outside funding for the lung cancers studies. It's possible larger studies will be initiated in the near future to support an eventual commercialization for lung.
    Jun 18 10:38 AM | Likes Like |Link to Comment
  • Sanuwave: DermaPACE Could Be Very Competitive In $2B Diabetic Foot Ulcer Market [View article]
    brewbob - yes, thanks for that - I do mean 2014
    Jun 13 08:43 AM | Likes Like |Link to Comment
  • Competitive Advantages, Huge Skin Cancer Market Bode Well For Aura [View article]
    gtcoogee,

    Pricing is still kind of a work in process and will likely be at least somewhat determined by what the market will bear as well as how much the device will cost to make - with some manuf volume. Right now, the guess is somewhere between $35k - $60k but also possible to have a lease option. There is a consumable - disposable, one-time use end cap - that right now is expected to sell for $10 and where most of the margin will be.
    Jun 6 09:17 AM | 1 Like Like |Link to Comment
COMMENTS STATS
76 Comments
13 Likes